

Kineret has received approval for a New Covid-19 Treatments Add-on Payment (NCTAP), and CMS will publish hospital coding instructions on its NCTAP website (<https://www.cms.gov/medicare/covid-19/new-covid-19-treatments-add-payment-nctap>).

- CMS expects to post the instructions within a short timeframe and will make the coding instructions retroactive to the date of the EUA, November 8, 2022. This means that any claims for cases where Kineret was administered before NCTAP coding instructions were published can be resubmitted for NCTAP.
- The instructions will advise hospitals that COVID-19 cases for discharge on or after November 8, 2022, where Kineret is administered, must have the following codes to receive NCTAP:
  - ICD-10-CM diagnosis code U.07.1 (COVID-19), AND
  - Kineret NDC # 66658-234-07
- Other instructions will likely state that hospitals should report the NDC(s) for all products administered during the stay, even if the hospital got the product for free. However, hospitals shouldn't report charges for products they get for free. Also, a hospital shouldn't seek additional payment on the claim for drugs or biologicals to treat patients with known or suspected COVID-19 that the government purchased or provided for free.

If there are specific medical questions, please Contact Medical Information by email or phone at: [Medinfo.us@sobi.com](mailto:Medinfo.us@sobi.com) / 1-866-773-5274.